September 12, 2019
New Real-World Data Support Long-Term Efficacy and Safety Profile of Mavenclad
Not intended for UK and U.S. based media Post-hoc analysis found 75% of patients from CLARITY and CLARITY Extension showed…
Pharmaceuticals, Biotechnology and Life Sciences
Not intended for UK and U.S. based media Post-hoc analysis found 75% of patients from CLARITY and CLARITY Extension showed…